CURE Pharmaceutical announced the addition of four key hires to their growing leadership team. Michael Redard will serve as its Chief Financial Officer. Josh Held becomes an independent new board member, Bhaumik Patel is company's director of new technologies and Teresa Virgallito will be a scientific advisor.

Patel, Virgallito and Held join CURE as a result of its recent acquisition of Chemistry Holdings Inc. Redard joins CURE with over 30 years of experience in financial operations, strategic planning and capital markets. His career has spanned a broad range of industries, including medical devices, healthcare, consumer products and manufacturing. Held is a third-generation entrepreneur whose diverse expertise spans finance, law, sales and marketing.

A forward-thinking innovator, he has broad experience in corporate development, deal origination, complex deal structures, legal planning, business succession planning, new brand build-outs, media planning, and cross-disciplinary leadership. Patel is an expert in drug encapsulation and has developed dosage forms such as tablets, soft gel and hard-shell capsules, pharmaceutical suspensions and semisolids. Virgallito has specialized in physical and mechanical encapsulation, ingredient engineering, food law regulations and food safety, microbiology and chemical instrumentation.